TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1897377
Drug: Physostigmine (acute,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (acute, intravenous administration)
Study: 6344699
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (5 mg preservative-free morphine sulfate in 10 ml saline)
Study: 8485789
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine
Study: 12623939
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg once daily
Study: 1662562
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg once daily
Study: 7959378
Drug: Invasive hemodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive hemodynamic monitoring and treatment before operation (group A)
Study: 28735368
Drug: MDMA (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (75 mg)
Study: 18201352
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of calcipotriol or maxacalcitol ointment before phototherapy
Study: 18201352
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of calcipotriol or maxacalcitol ointment after phototherapy
Study: 30808949
Drug: Extensively hydrolyzed
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extensively hydrolyzed casein formula containing the probiotic L.rhamnosus GG (EHCF + LGG)
Study: 28181192
Drug: Dual-pill combination
Normalized name: Tums Dual Action Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-pill combination of perindopril 5 mg/indapamide 1.25 mg + amlodipine 5 mg (Per/Ind + Aml)
Study: 23190017
Drug: Fostamatinib suspension
Normalized name: fostamatinib
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib suspension
Study: 23190017
Drug: Fostamatinib tablet
Normalized name: fostamatinib
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib tablet
Study: 16527796
Drug: NTI under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NTI under curve-tipped suction catheter (CTSC) guidance (G[+] group)
Study: 16527796
Drug: NTI without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NTI without CTSC guidance (G[‐] group)
Study: 7020093
Drug: Niclofolan 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niclofolan 2 mg/kg
Study: 23823347
Drug: Chemomechanical method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemomechanical method (papain gel)
Study: 18851956
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/day for 4 weeks)
Study: 8708970
Drug: Systemic beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic beta-blockers
Study: 7062419
Drug: Cyclophosphamide, methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy
Study: 19794082
Drug: Vorinostat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (200 mg three times daily for 14 days followed by 1 week rest) in arm B
Study: 15547458
Drug: naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone 50 mg daily plus usual program treatment
Study: 15547458
Drug: placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus usual treatment
Study: 9000657
Drug: HAT 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAT 0.5 mg/kg/week (n=4)
Study: 9000657
Drug: HAT 1
Normalized name: brompheniramine maleate/pseudoephedrine HCl/codeine phosphat 1.3 mg-10 mg-6.3 mg/5 mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAT 1 mg/kg/week (n=2)
Study: 9000657
Drug: HAT 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAT 0.5 mg/kg every other week (n=3)
Study: 9000657
Drug: HAT 1
Normalized name: brompheniramine maleate/pseudoephedrine HCl/codeine phosphat 1.3 mg-10 mg-6.3 mg/5 mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAT 1 mg/kg every other week (n=3)
Study: 8272759
Drug: Different inclusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different inclusion criteria for treatment
Study: 3548336
Drug: Low-dose controlled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose controlled heparin anticoagulation
Study: 30541572
Drug: Proprietary spearmint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary spearmint extract (PSE) 900 mg daily for 90 days
Study: 27184721
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (CT+bevacizumab)
Study: 29777975
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (CT)
Study: 12974145
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin and metformin
Study: 11453959
Drug: Human regular
Normalized name: Human regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human regular insulin
Study: 1534044
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 or 10 mg/day od)
Study: 1534044
Drug: Nifedipine s.r.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine s.r. (20 or 40 mg BID)
Study: 3956558
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of pethidine im
Study: 3956558
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of extradural pethidine
Study: 3956558
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of extradural pethidine
Study: 20137477
Drug: rhPTH (1-34)
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhPTH (1-34) 20 microg daily
Study: 20979784
Drug: elcatonin 20
Normalized name: melatonin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: elcatonin 20 U weekly
Study: 16703579
Drug: Aztreonam lysinate
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aztreonam lysinate for inhalation (AI) 75 mg
Study: 16703579
Drug: Aztreonam lysinate
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aztreonam lysinate for inhalation (AI) 150 mg
Study: 16703579
Drug: Aztreonam lysinate
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aztreonam lysinate for inhalation (AI) 225 mg (adolescents)
Study: 16703579
Drug: Aztreonam lysinate
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aztreonam lysinate for inhalation (AI) 75 mg (adults)
Study: 16703579
Drug: Aztreonam lysinate
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aztreonam lysinate for inhalation (AI)
Study: 11878737
Drug: PCEA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA plus night-time infusion
Study: 823586
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg chlordiazepoxide
Study: 26408873
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus glimepiride (3mg once daily)
Study: 26408873
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus gliclazide (80 mg once daily)
Study: 21645895
Drug: ethinilestradiol (EE)
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinilestradiol (EE) 0.020 mg + DRSP 3 mg
Study: 21645895
Drug: ethinilestradiol (EE)
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinilestradiol (EE) 0.020 mg + desogestrel 0.15 mg
Study: 15138107
Drug: lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine 100 mg daily
Study: 9732194
Drug: Saline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (2 ml) administered intramuscularly 45 min before ESWL
Study: 28274234
Drug: Sapropterin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapropterin (10 mg/kg/day) plus phenylalanine-restricted diet
Study: 21419010
Drug: Local anesthetics
Normalized name: LOCAL ANESTHETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetics plus 2 µg/kg buprenorphine (B group)
Study: 21419010
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection 2 µg/kg buprenorphine before anesthesia (C group)
Study: 15932835
Drug: Bazedoxifene 20
Normalized name: bazedoxifene 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 20 mg/d
Study: 15932835
Drug: Bazedoxifene 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 40 mg/d
Study: 11408508
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/d
Study: 12679422
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (9.6 micro g/kg body weight.d)
Study: 10487455
Drug: Topical mupirocin
Normalized name: mupirocin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mupirocin therapy
Study: 31983237
Drug: Topical proparacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical proparacaine 0.5% (additional drop)
Study: 31983237
Drug: Topical proparacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical proparacaine 0.5% and povidone iodine
Study: 19875482
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH), 2 mg/d subcutaneously for 8 weeks
Study: 11171825
Drug: Phenylephrine gel
Normalized name: LIDOCAINE 50 mg in 1 g / PHENYLEPHRINE HYDROCHLORIDE 2.5 mg in 1 g TOPICAL GEL [SECONDARY NUMB Lidocaine Phenylephrine Gel]
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine gel 20%
Study: 30577404
Drug: Initial radiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial radiation therapy
Study: 11939936
Drug: Entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (200 mg)
Study: 1743245
Drug: Nitrazepam 5
Normalized name: nitrazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 5 mg/d
Study: 31467115
Drug: Inhaled α1-antitrypsin
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled α1-antitrypsin (AAT) 80 mg solution, twice daily for 50 weeks
Study: 24639423
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium nitrite (70 μmol) administered over 5 min immediately before primary percutaneous intervention (PPCI)
Study: 24639423
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching infusion)
Study: 20206784
Drug: L‐AmB 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐AmB 5 mg/kg per week
Study: 10489946
Drug: Continued medication
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medication
Study: 2414253
Drug: Bleomycin injected
Normalized name: bleomycin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin injected intramuscularly 1 hour before radiation treatment daily for 5 days a week
Study: 19237438
Drug: Heparin-bonded catheters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded catheters
Study: 19237438
Drug: Standard non-heparin-bonded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard non-heparin-bonded catheters
Study: 28216062
Drug: Nalmefene (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene (18 mg)
Study: 29729957
Drug: GM-SR 4/1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-SR 4/1000 mg once-daily
Study: 24123094
Drug: Dose C
Normalized name: Naprelan Dose Card
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose C (10 mg mane and 5 mg tarde)
Study: 24123094
Drug: Dose B
Normalized name: Aldose beta-D-fructosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose B (10 mg mane and 10 mg tarde)
Study: 24123094
Drug: Dose A
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose A (20 mg mane and 10 mg tarde)
Study: 21364772
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (DA) therapy
Study: 21364772
Drug: No DA
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No DA therapy (off DA therapy)
Study: 19343887
Drug: OXY‐TDS (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXY‐TDS (transdermal oxybutynin)
Study: 10871974
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 or 30 mg once daily
Study: 29480324
Drug: EGCG-concentrated green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG-concentrated green tea extract (GTE) low dose
Study: 29480324
Drug: EGCG-concentrated green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG-concentrated green tea extract (GTE) high dose
Study: 16505520
Drug: Parenteral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral group
Study: 16454441
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/d)
Study: 10344062
Drug: Enalapril 2.5
Normalized name: enalapril 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 2.5 mg
Study: 10938492
Drug: Perindopril 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2.0 mg
Study: 8392282
Drug: Enalaprilat 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat 1.5 mg (intravenous)
Study: 24671453
Drug: Oral rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rabeprazole 20 mg twice daily for 5 days before ESD
Study: 24671453
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily for 5 days before ESD
Study: 19062727
Drug: Dose-dense chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense chemotherapy with paclitaxel (175 mg/m2) and epirubicin (60 mg/m2) every two weeks
Study: 28196674
Drug: Dose-dense chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense chemotherapy
Study: 19062727
Drug: Regular chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular chemotherapy
Study: 15452681
Drug: Placebo (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control) with low dose methamphetamine (15 mg)
Study: 15452681
Drug: Placebo (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control) with high dose methamphetamine (30 mg)
Study: 12593523
Drug: Beclometasone dipropionate
Normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclometasone dipropionate (BDP) suspension for nebulization 1,600 microg day(‐1) b.i.d. (n = 75)
Study: 12593523
Drug: Beclometasone dipropionate
Normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclometasone dipropionate (BDP) spray 800 microg day(‐1) b.i.d. via metered-dose inhaler (MDI) plus spacer (n = 76)
Study: 10578788
Drug: Routine nipple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine nipple care including an ointment (control group)
Study: 10578788
Drug: Avoidance of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoidance of nipple creams and other products (intervention group)
Study: 8554224
Drug: 23‐polyvalent pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23‐polyvalent pneumococcal polysaccharide vaccine
Study: 1677625
Drug: PGE2 vaginal
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 vaginal tablets
Study: 2195577
Drug: Clonidine (oral)
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine (oral)
Study: 6129951
Drug: Propanolol (oral)
Normalized name: Propanolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propanolol (oral)
Study: 26156651
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg per day)
Study: 21761999
Drug: Carbetocin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (single dose)
Study: 21761999
Drug: Oxytocin (infusion)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (infusion)
Study: 16881500
Drug: Ametop (amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ametop (amethocaine gel) applied to a digit for 30 minutes before capillary sampling
Study: 16765148
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray
Study: 11349825
Drug: Candesartan cilexetil/HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan cilexetil/HCTZ, 16/12.5 mg once daily
Study: 11349825
Drug: Candesartan cilexetil/placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan cilexetil/placebo, 16 mg once daily
Study: 3150273
Drug: Conventional immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppressive therapy
Study: 19258430
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rhGH treatment)
Study: 2135068
Drug: Actovegin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin (250 ml 20%)
Study: 19803573
Drug: Cultural congruence
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultural congruence in treatment
Study: 16940452
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy at a mean maintenance dose of 0.31 mg/d in elderly GHD patients
Study: 16940452
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy at a mean maintenance dose of 0.44 mg/d in younger GHD patients
Study: 14525770
Drug: Itraconazole (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (oral solution 2.5 mg/kg 3 times daily, or intravenous 200 mg daily)
Study: 10577295
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg/d)
Study: 2960861
Drug: Etretin (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretin (0, 25, or 50 mg/day for 8 weeks, followed by 25, 50, or 75 mg/day for optimal response)
Study: 30206079
Drug: Advice, exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice, exercises and soft-tissue treatment plus manipulative therapy
Study: 30206079
Drug: Advice, exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice, exercises and soft-tissue treatment
Study: 27257748
Drug: Formulation letters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation letters that paid attention to the development of AN
Study: 24292991
Drug: Clarithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (1 g intravenously once daily for 4 days)
Study: 20394631
Drug: C/BPO +
Approvals — FDA: no, EMA: no, PMDA: no
Description: C/BPO + PDL treatment (wavelength 585 nm, energy fluence 3 J cm(‐2), pulse duration 0.35 ms, spot size 7 mm)
Study: 12100223
Drug: rizatriptan 10
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rizatriptan 10 mg oral
Study: 318951
Drug: Pentazocine 25
Normalized name: pentazocine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 25 mg and Aspirin 325 mg (PA-L)
Study: 318951
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg of Aspirin (A650)
Study: 318951
Drug: Pentazocine 50
Normalized name: pentazocine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 50 mg and Aspirin 650 mg (PA-H)
Study: 30979460
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus with standard-dose corticosteroids
Study: 30979460
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus with reduced-dose corticosteroids
Study: 31056218
Drug: Drug (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug (exact dosage and duration not specified)
Study: 23506415
Drug: Optimal current
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal current step-up practice (medical treatment followed by endoscopic interventions and surgery if needed)
Study: 19508745
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy for MRKH (CBT-MRKH)
Study: 15477790
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg/day) for 6 weeks
Study: 12204014
Drug: Doxazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (2 to 8 mg/d)
Study: 15983290
Drug: Chlorthalidone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5 to 25 mg/d)
Study: 26489704
Drug: DMARD+adalimumab group
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DMARD+adalimumab group (adalimumab 40 mg/every other week)
Study: 19841966
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (10 mg/kg initially, then two 5 mg/kg doses 24 h apart)
Study: 16185378
Drug: Risperidone (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (average final dose 1.6 mg/day)
Study: 8596125
Drug: 300 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ng/ml exogenous Plasmodium falciparum antigens
Study: 8596125
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with P. falciparum malaria after 4 weeks of chemotherapy
Study: 26824942
Drug: Ganciclovir-Valganciclovir dosing
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir-Valganciclovir dosing adjusted based on Bayesian prediction model (group B)
Study: 15991263
Drug: Guidelines plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines plus ATP (Atepadene, 90 mg daily for 30 days)
Study: 8938674
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (lisinopril or enalapril)
Study: 27832799
Drug: VMAT (Volumetric
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMAT (Volumetric Modulated Arc Therapy)